HOME >> BIOLOGY >> NEWS
Enzyme inhibitor produces stable disease in patients with advanced solid cell cancers

Prague, Czech Republic: Preliminary trials of a MEK enzyme inhibitor have shown that it is capable of producing long-lasting stable disease in patients with advanced solid cancers. Tests showed that the drug inhibited key targets in the patients' tumours, and now it is being tested in phase II clinical trials.

Professor Alex Adjei told the EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Prague today (Wednesday 8 November) that the drug AZD6244 (ARRY-142886) [2] inhibited MEK1/2 an enzyme that plays an important role in the Ras/Raf/MEK/ERK cell signalling pathway, which regulates cell proliferation and survival. Activation of this pathway has been implicated in a number of cancers, including lung, pancreatic, colon, melanoma and thyroid cancer.

"Laboratory studies have shown that AZD6244 has an effect on human tumours at nanomolar concentrations, and the first part of the phase I clinical trial has determined the maximum tolerated dose and the safety of the compound. Results from this second part of the trial demonstrate that a dose of 100mg of AZD6244 is well tolerated, produces a high incidence of long-lasting stable disease, and is associated with a profound inhibition of the cell signalling protein pERK and a reduction in cell proliferation which indicates that the drug is working against the tumours," said Prof Adjei, who was professor of oncology at the Mayo Clinic, Rochester, USA, before moving in October to be the senior vice-president for clinical research and chair of the Department of Medicine at the Roswell Park Cancer Institute, Buffalo, USA.

Prof Adjei and his colleagues at the Mayo Clinic, University of Colorado Health Sciences Center and Fox Chase Cancer Center recruited into the second part of the trial 34 patients with advanced cancers, including melanoma, breast, lung and colorectal cancers. Approximately 40% of the patients had melanoma. The researchers were particularly intere
'"/>

Contact: Emma Mason
wordmason@mac.com
44-077-112-96986
European Organisation for Research and Treatment of Cancer
8-Nov-2006


Page: 1 2 3

Related biology news :

1. Enzyme discovery sheds light on vitamin D
2. Enzyme delivered in smaller package protects cells from radiation damage
3. Enzyme Engineering XIX
4. Enzyme shreds Alzheimers protein
5. Enzyme defect leads to hyperinsulinism
6. Eat less, weigh more? Enzyme makes lean mice susceptible to dietary fat
7. Enzyme crystal structure reveals unexpected genome repair functions
8. Enzyme inhibitors block replication of SARS virus
9. Enzyme may be target for new anti-inflammatory compounds
10. Enzyme action creates protein linked to Alzheimers disease
11. Enzyme deficiency may contribute to liver cancer, Mount Sinai research indicates

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/2/2018)... ... October 02, 2018 , ... ... to 27th, 2018 at Tampa Convention Center. The Palo Alto-based face recognition company, ... session on September 27th. Other speakers included U.S. Federal executives from Department of ...
(Date:10/1/2018)... (PRWEB) , ... October 01, 2018 , ... ... MDLIVE and 1200+ customers and InteloMed, the leading patient monitoring technology providing real-time ... vital signs and other indications of patient health during a telehealth visit without ...
(Date:9/28/2018)... ... 28, 2018 , ... Purification , The fluorescent-dye labeled bacmid DNA must be ... Kit. Samples were gently mixed with 275 µL of provided PB buffer (Qiagen), applied ... room temperature. Flow-through was discarded and 750 µL of provided PE buffer (Qiagen) was ...
Breaking Biology News(10 mins):
(Date:9/22/2018)... ... September 20, 2018 , ... Catalent Pharma Solutions, the leading ... consumer health products, today announced that it will be co-hosting a workshop with ... Development,”. The one-day event is to be held at the Hilton Boston Back ...
(Date:9/15/2018)... ... September 14, 2018 , ... Next-generation genomic sequencing is transforming what is ... challenges remain. In the past, the sheer size of genomics data has made sharing ... new data ecosystem developed to advance cures by reducing the technological barriers to data ...
(Date:9/13/2018)... ... September 13, 2018 , ... Asymmetrex’s director, James L. Sherley, M.D., ... in medicine, if we didn’t have the means to measure the number of drug ... answer, “Nowhere! And that is what’s holding up progress in stem cell medicine.” , ...
(Date:9/12/2018)... ... September 11, 2018 , ... Leading regenerative veterinary medicine ... Practitioners Conference (AAFP) later this month. The company’s CEO and founder, ... the treatment of chronic kidney disease in felines at a poster session on ...
Breaking Biology Technology:
Cached News: